A landmark MHRA approval opens a new treatment pathway for one of cardiology's most challenging patient groups — and continuing professional development is key to confident prescribing.
Heart failure with preserved ejection fraction (HFpEF) and mildly reduced ejection fraction (HFmrEF) has long been called the "forgotten" heart failure — a condition affecting millions of patients yet historically underserved by evidence-based pharmacological options. That changed with the recent MHRA approval of finerenone, a non-steroidal mineralocorticoid receptor antagonist, for use in this population.
For GPs, cardiologists, pharmacists, and nurse practitioners working across primary and secondary care, this approval signals a meaningful shift in heart failure management. But with new treatment options comes the need for updated clinical knowledge, confident patient conversations, and clear prescribing pathways.
What Is Finerenone — and Why Does This Approval Matter?
Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist (MRA) — pharmacologically distinct from older steroidal MRAs such as spironolactone and eplerenone. Its approval for HFpEF and HFmrEF represents a significant expansion of the therapeutic toolkit for a patient group that has, until now, had few guideline-directed pharmacological options.
This matters because HFpEF accounts for up to 50% of all heart failure cases, disproportionately affecting older women, patients living with obesity, those with hypertension, and patients with type 2 diabetes — populations that are often clinically complex and require coordinated care across primary and secondary settings.
What Clinicians Should Consider Following the Finerenone Approval
With finerenone now approved, multidisciplinary teams should be reviewing four priority areas:
1. Patient Eligibility
Identify patients within your existing heart failure cohort who may benefit from finerenone under current MHRA and NICE guidance.
2. Safe Prescribing and Monitoring
Renal function and serum potassium remain central to safe MRA prescribing. Baseline and follow-up monitoring protocols should be embedded in your clinical workflow.
3. Multidisciplinary Communication
Ensure GP, cardiology, and pharmacy teams are aligned on initiation, titration, and ongoing review responsibilities for patients commencing finerenone.
4. Patient Education
Support patients in understanding this new addition to their care plan — particularly around adherence, side-effect awareness, and the importance of monitoring appointments.
Stay Ahead with CliniLink CPD-Accredited Events
At CliniLink, we bring together expert-led education designed to keep clinicians clinically confident and current with developments exactly like the finerenone approval. Whether you're a GP, cardiologist, pharmacist, or advanced nurse practitioner, our CPD-accredited cardiology events cover the evolving cardiovascular landscape.
🫀 Heart Failure Masterclass — Live Webinar (MS Teams)
A deep dive into updated heart failure guidelines, new pharmacological approvals including finerenone, and practical prescribing advice from leading UK cardiologists. Earn CPD points from your desk.
🏥 Cardiovascular Deep Dive — Face-to-Face
An interactive, case-based day exploring real-world cardiology challenges including HFpEF management, finerenone prescribing, risk stratification, and multimorbidity. Available in London, Manchester, Birmingham, and Leeds. Our CVRM face-to-face masterclasses cover the full cardiovascular, renal and metabolic spectrum — giving you the confidence to manage complex, comorbid patients across primary and secondary care.
- Deep Dive CVRM Masterclass: From Evidence to Implementation
- Deep Dive Cardiovascular, Renal and Metabolism (CVRM) Masterclass
📋 Primary Care Cardiology Update
Designed for GPs and community prescribers, this session bridges secondary care guidance with practical primary care application — covering diagnostics, referral pathways, and medication optimisation.
Why CPD Matters Right Now
Approvals like finerenone don't exist in isolation. They arrive alongside updated NICE guidance, changing prescribing responsibilities, and patients who are increasingly informed and engaged. Staying current isn't just good practice — for many clinicians, it's a revalidation and appraisal requirement.
Every CliniLink event is:
- ✅ CPD-accredited — count towards your annual learning requirements
- ✅ Clinically relevant — grounded in real guidelines and real cases
- ✅ Flexible — online webinars and in-person sessions across the UK
- ✅ Multidisciplinary — designed for GPs, nurses, pharmacists, and specialists
Learn at Your Own Pace with CliniLink Academy
Can't make a live event? The CliniLink Academy gives you on-demand access to a growing library of cardiovascular CPD courses — including content covering cardiorenal metabolic disease, HFpEF, lipid management, CKD, and more. Learn at your own pace, in your own time, and apply it directly to your clinical practice.
🎓 Get an annual CliniLink Academy subscription for just £39.99 — use code CPD20 at checkout for an exclusive discount on your annual membership and unlock unlimited access to our full cardiovascular and multidisciplinary course library.
👉 Browse cardiovascular CPD courses on CliniLink Academy
Register for a CliniLink Cardiology CPD Event
Don't let pivotal developments like the finerenone approval for HFpEF and HFmrEF pass you by. Whether you prefer the convenience of a webinar, the depth of a face-to-face Deep Dive, or the flexibility of on-demand learning through CliniLink Academy, we have a format that fits your schedule — and your revalidation goals.
👉 Browse upcoming cardiology CPD events and register with CliniLink
Spaces at our face-to-face events are limited — early booking is strongly recommended.